Search details
1.
Testosterone levels and androgen receptor copy number variations in castration-resistant prostate cancer treated with abiraterone or enzalutamide.
Prostate
; 79(11): 1211-1220, 2019 08.
Article
in English
| MEDLINE | ID: mdl-31251826
2.
Immune System and DNA Repair Defects in Ovarian Cancer: Implications for Locoregional Approaches.
Int J Mol Sci
; 20(10)2019 May 25.
Article
in English
| MEDLINE | ID: mdl-31130614
3.
Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer.
BMC Cancer
; 18(1): 1267, 2018 Dec 19.
Article
in English
| MEDLINE | ID: mdl-30567527
4.
A Phase II Study of Everolimus Plus Oral Prednisone in Patients with Metastatic Renal Cell Cancer.
Oncologist
; 22(7): 784-e74, 2017 07.
Article
in English
| MEDLINE | ID: mdl-28546463
5.
(18)F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide.
Eur J Nucl Med Mol Imaging
; 42(8): 1276-83, 2015 Jul.
Article
in English
| MEDLINE | ID: mdl-25808631
6.
Chromogranin A is a potential prognostic marker in prostate cancer patients treated with enzalutamide.
Prostate
; 74(16): 1691-6, 2014 Dec.
Article
in English
| MEDLINE | ID: mdl-25262981
7.
Inherited Mutations in DNA Damage Repair Genes in Italian Men with Metastatic Prostate Cancer: Results from the Meet-URO 10 Study.
Eur Urol Open Sci
; 61: 44-51, 2024 Mar.
Article
in English
| MEDLINE | ID: mdl-38384439
8.
Multicenter institutional experience of surgically resected thymic epithelial tumors (TETs): an observational report on behalf of F.O.N.I.C.A.P. (Forza Operativa Nazionale Interdisciplinare Contro il Cancro del Polmone).
Ann Surg Oncol
; 20(9): 2958-63, 2013 Sep.
Article
in English
| MEDLINE | ID: mdl-23709100
9.
Impact of the time interval between primary or interval surgery and adjuvant chemotherapy in ovarian cancer patients.
Front Oncol
; 13: 1221096, 2023.
Article
in English
| MEDLINE | ID: mdl-37664032
10.
Melphalan as a Promising Treatment for BRCA-Related Ovarian Carcinoma.
Front Oncol
; 11: 716467, 2021.
Article
in English
| MEDLINE | ID: mdl-34367999
11.
Erratum to: (18)F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide.
Eur J Nucl Med Mol Imaging
; 42(8): 1337-8, 2015 Jul.
Article
in English
| MEDLINE | ID: mdl-25900277
12.
Potential Application of Chimeric Antigen Receptor (CAR)-T Cell Therapy in Renal Cell Tumors.
Front Oncol
; 10: 565857, 2020.
Article
in English
| MEDLINE | ID: mdl-33072597
13.
Enzalutamide for the treatment of nonmetastatic castration-resistant prostate cancer.
Expert Opin Pharmacother
; 21(17): 2091-2099, 2020 Dec.
Article
in English
| MEDLINE | ID: mdl-32783772
14.
Inflammatory Biomarkers as Predictors of Response to Immunotherapy in Urological Tumors.
J Oncol
; 2019: 7317964, 2019.
Article
in English
| MEDLINE | ID: mdl-31641355
15.
Caregiver Emotional Burden in Testicular Cancer Patients: From Patient to Caregiver Support.
Front Endocrinol (Lausanne)
; 10: 318, 2019.
Article
in English
| MEDLINE | ID: mdl-31191451
16.
Plasma Androgen Receptor in Prostate Cancer.
Cancers (Basel)
; 11(11)2019 Nov 04.
Article
in English
| MEDLINE | ID: mdl-31689899
17.
Multimodal Approach to Outcome Prediction in Metastatic Castration-Resistant Prostate Cancer by Integrating Functional Imaging and Plasma DNA Analysis.
JCO Precis Oncol
; 3: 1-13, 2019 Dec.
Article
in English
| MEDLINE | ID: mdl-35100689
18.
AR Copy Number and AR Signaling-directed Therapies in Castrationresistant Prostate Cancer.
Curr Cancer Drug Targets
; 18(9): 869-876, 2018.
Article
in English
| MEDLINE | ID: mdl-29173173
19.
Plasma androgen receptor and serum chromogranin A in advanced prostate cancer.
Sci Rep
; 8(1): 15442, 2018 10 18.
Article
in English
| MEDLINE | ID: mdl-30337589
20.
Association among metabolic syndrome, inflammation, and survival in prostate cancer.
Urol Oncol
; 36(5): 240.e1-240.e11, 2018 05.
Article
in English
| MEDLINE | ID: mdl-29402534